Journal Article Summary
The article investigates the safety of adalimumab, a medication used to treat conditions like hidradenitis suppurativa (HS) and psoriasis, when administered either every week (EW) or every other week (EOW). Understanding the safety of different dosing schedules is crucial, as it can help optimize treatment plans for patients suffering from these chronic inflammatory conditions. Adalimumab is known for its effectiveness, but like all medications, it carries potential risks, making it important to evaluate how different dosing regimens might impact patient safety.
The study analyzed data from multiple clinical trials involving patients with HS and psoriasis, comparing the safety profiles of the two dosing schedules. The findings indicated that there were no new safety risks associated with the EW dosing compared to the EOW regimen. Overall, the safety profiles for both dosing schedules were similar, with adverse events occurring at comparable rates across the groups. This included data from studies on other conditions treated with adalimumab, such as Crohn's disease and rheumatoid arthritis, which further supported the conclusion that both dosing regimens are generally safe.
However, the study does have limitations, including a relatively short duration for some trials and variations in patient populations across different studies. Patients should be aware that while the overall safety profile appears consistent, individual responses to medication can vary. It is advisable for patients to discuss their treatment options, including dosing frequency and any concerns about side effects, with their healthcare provider to ensure the best approach tailored to their specific needs.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Ryan Caitriona, Sobell Jeffrey M., Leonardi Craig L., Lynde Charles W., Karunaratne Mahinda, Valdecantos Wendell C., Hendrickson Barbara A.. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. American Journal of Clinical Dermatology 2018. DOI: 10.1007/s40257-017-0341-6. PMID: 29380251. PMCID: PMC5945711.
Featured Pill Pals Product
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription may be required.
